Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Sarcoma × olaratumab × Clear all

Phase

Phase 1 5 Phase 3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 1 Pancreatic Neoplasms 1

Interventions

Radiotherapy 12 Gemcitabine 12 Doxorubicin 11 pembrolizumab 10 Nivolumab 7 Docetaxel 7 Cyclophosphamide 6 pazopanib 5 Ifosfamide 5 Filgrastim 5 Temozolomide 4 Imatinib Mesylate 4 130-nm albumin-bound paclitaxel 4 talimogene laherparepvec 3 eribulin 3 Vinorelbine 3 Sirolimus 3 PM 01183 3 Irinotecan 3 Ipilimumab 3 Drug Therapy 3 Cisplatin 3 Albumin-Bound Paclitaxel 3 surufatinib 2 selinexor 2 repotrectinib 2 poly ICLC 2 pegfilgrastim 2 liposomal doxorubicin 2 avelumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01185964 2017-04-14

A Study of Olaratumab in Soft Tissue Sarcoma

Eli Lilly and Company

Phase 1/2 Completed

148 enrolled 21 charts

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡